Rui-Xi Sun

Rui-Xi Sun

Auto-generated profile, based on publicly available information

Rui-Xi Sun

Institute of Basic Theory, China Academy of Chinese Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
RSRui-Xi Sun
Rui-Xi Sun
WHWeijun Huang
Weijun Huang
YXYao Xiao
Yao Xiao
DWDou-Dou Wang
Dou-Dou Wang
GMGuo-Hua Mu
Guo-Hua Mu
JZJinxi Zhao
Jinxi Zhao
Shenlian (SL) decoction is a herbal formula composed of Coptis and ginseng, of which berberine and ginsenoside are the main constituents. Even though SL decoction is widely used in treating diabetes in China, the mechanism of its antidiabetes function still needs further study. Gut microbiota disorder is one of the important factors that cause diabetes. To explore the effect of SL decoction on intestinal microbiota, gut microbiota of mice was analyzed by sequencing the gut bacterial 16S rRNA V3+V4 region and metagenomics. In this study, results demonstrated that SL decoction had a better hypoglycemic effect and β cell protection effect than either ginseng or Coptis chinensis. Alpha diversity analysis showed that all interventions with ginseng, Coptis, and SL decoction could reverse the increased diversity and richness of gut microbiota in db/db mice. PCoA analysis showed oral SL decoction significantly alters gut microbiota composition in db/db mice. 395 OTUs showed significant differences after SL treatment, of which 37 OTUs enriched by SL decoction showed a significant negative correlation with FBG, and 204 OTUs decreased by SL decoction showed a significant positive correlation with FBG. Results of KEGG analysis and metagenomic sequencing showed that SL decoction could reduce the Prevotellaceae, Rikenellaceae, and Helicobacteraceae, which were related to lipopolysaccharide biosynthesis, riboflavin metabolism, and peroxisome, respectively. It could also upregulate the abundance of Bacteroidaceae, which contributed to the metabolism of starch and sucrose as well as pentose-glucuronate interconversions. In the species level, SL decoction significantly upregulates the relative abundance of Bacteroides_acidifaciens which showed a significant negative correlation with FBG and was reported to be a potential agent for modulating metabolic disorders such as diabetes and obesity. In conclusion, SL decoction was effective in hypoglycemia and its mechanism may be related to regulating gut microbiota via upregulating Bacteroides_acidifaciens.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
YLYi-Fan Liu
Yi-Fan Liu
YLYuan-Yuan Liu
Yuan-Yuan Liu
WTWen-Yi Tian
Wen-Yi Tian
YXYao Xiao
Yao Xiao
WHWeijun Huang
Weijun Huang
JZJinxi Zhao
Jinxi Zhao
Background: Diabetic kidney disease (DKD) is a major global cause of end‐stage renal disease. Emerging evidence suggests that hypoxia is a critical factor in the advancement of DKD. Traditional Chinese medicine (TCM) is an effective alternative therapy for DKD. The Qi‐Gui‐Sheng‐Jiang‐San (QGSJS) decoction is an effective formula for treating DKD clinically, and its mechanism may be related to regulating hypoxia response, necessitating further investigation and a thorough analysis of the underlying biological mechanisms. Methods: Initially, we employed network pharmacology methods to collect and screen the active constituents of the QGSJS decoction from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant chemical databases. Subsequently, the targets of these active components were predicted via the PubChem and TCMSP databases, while relevant targets associated with DKD were sourced from GeneCards, OMIM, and DrugBank. In the second phase, we built a protein–protein interaction (PPI) network via the STRING database to identify core targets. This was followed by GO and KEGG enrichment analyses to assess if the QGSJS decoction′s mechanisms of action are linked to hypoxic response regulation. Finally, in vivo experiments were performed to confirm the findings from the network pharmacology analysis and to comprehensively elucidate the QGSJS decoction′s mechanisms of action. Results: The network pharmacology analysis revealed 57 active components in the QGSJS decoction, capable of influencing 72 targets associated with DKD. Quercetin, kaempferol, and isorhamnetin are likely to be the key constituents of the QGSJS decoction. The PPI network suggests that HIF1A serves as a hub gene, closely associated with IL6, NFKBIA, and VEGFA. Enrichment analysis indicates that the QGSJS decoction modulates the HIF‐1 signaling pathway and impacts biological processes and molecular functions linked to HIF‐1 α . In vivo studies demonstrate the QGSJS decoction′s renal protective properties, suppressing the expression of HIF‐1 α , p‐STAT3, p‐Akt, VEGF, VEGFR, p‐NF‐ κ B, and NOTCH1 in the kidneys without affecting PHD2. Conclusion: The QGSJS decoction primarily inhibits HIF‐1 α through non–oxygen‐dependent pathways, mitigating damage related to abnormal hypoxic responses, which may be the main mechanism through which it protects the kidneys.

6 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
YLYi-Fan Liu
Yi-Fan Liu
YLYuan-Yuan Liu
Yuan-Yuan Liu
YXYao Xiao
Yao Xiao
WHWeijun Huang
Weijun Huang
RSRui-Xi Sun
Rui-Xi Sun
JZJinxi Zhao
Jinxi Zhao
Background: Shenlian (SL) decoction, a renowned traditional Chinese formula for diabetes mellitus, has also been employed to treat intestinal disorders. Previous studies have demonstrated the efficacy of SL decoction in regulating blood glucose and intestinal bacteria. Nevertheless, further analysis is required to elucidate the mechanistic link between SL decoction–mediated improvement of intestinal function and treatment of Type 2 diabetes mellitus (T2DM). Methods: Firstly, the active ingredients of SL decoction were sourced from the Traditional Chinese Medicine System Pharmacology (TCMSP) database, with putative targets of active ingredients being predicted using the same database. Secondly, the Online Mendelian Inheritance in Man (OMIM) and GeneCards databases were employed to screen the aforementioned targets that act on T2DM, and protein–protein interaction (PPI) networks were constructed in accordance with the results. Thirdly, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted using the Database for Annotation, Visualization, and Integrated Discovery (DAVID), which resulted in a comprehensive analysis of the association between SL decoction for the treatment of T2DM and the modulation of intestinal functions. Finally, the effect of the SL decoction on predicted lipopolysaccharide (LPS)‐related targets, as well as intestinal function markers, was validated through in vivo experimentation. Results: A total of 36 active ingredients and 145 potential targets of SL decoction were predicted. GO enrichment analysis indicated that the principal biological processes by which the SL decoction acted against T2DM were responses to LPSs, while KEGG enrichment analysis identified the nuclear factor kappa B (NF‐ κ B) signaling pathway and toll‐like receptor signaling pathway as the key pathways involved. The in vivo experiments showed that SL decoction improved glycolipid metabolism indexes, inflammatory factor levels, and LPS levels in db/db mice. The immunohistochemical results demonstrated that the SL decoction restored the expression of Occludin, Claudin‐1, and ZO‐1 in the intestine and inhibited the expression of toll‐like receptor 4 (TLR4), myeloid differentiation primary response gene 88 (MYD88), and NF‐ κ B in both the intestine and pancreas. Furthermore, it may influence the levels of short‐chain fatty acids (SCFAs) in feces. Conclusions: This research investigated the multigene pharmacological mechanism of SL decoction against T2DM using network pharmacology and in vivo experiments. SL decoction treatment of T2DM may reverse inflammation by inhibiting LPS‐related pathway activation and improving intestinal function.